Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DILAUDID-HP vs ALPHADROL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Hydromorphone is a full mu-opioid receptor agonist with high affinity for mu-opioid receptors, producing analgesia, euphoria, and sedation. It also binds to kappa and delta opioid receptors with lower affinity.
Selective glucocorticoid receptor agonist with high potency, binding to the glucocorticoid receptor and modulating gene transcription, leading to anti-inflammatory and immunosuppressive effects.
Management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate (FDA-approved),Off-label: Treatment of acute pain, postoperative pain, cancer pain, and breakthrough pain
Adjunctive therapy for short-term administration in severe allergic reactions,Management of inflammatory and autoimmune conditions,Off-label: Treatment of certain cancers (e.g., multiple myeloma, lymphoid malignancies)
Initial dose: 0.2-0.6 mg IV/IM/SC every 2-4 hours as needed; usual adult dose: 0.2-0.4 mg IV/IM/SC. Oral: 1-2 mg every 3-6 hours. Dose titration based on pain severity.
0.5 mg intravenously every 4 hours as needed; maximum 2 mg/day.
Terminal elimination half-life: 2.3–4 hours. In clinical context, consistent with dosing interval of 4–6 hours for immediate-release formulations; prolonged in hepatic or renal impairment.
Terminal elimination half-life of 12-15 hours in healthy adults; prolonged in renal impairment (up to 30 hours) requiring dose adjustment.
Hydromorphone is extensively metabolized in the liver via glucuronidation to hydromorphone-3-glucuronide (major metabolite) and to a lesser extent via reduction to dihydroisomorphine and dihydromorphine. Minor CYP2C9 and CYP3A4 involvement.
Hepatic via CYP3A4; undergoes extensive first-pass metabolism.
Renal: predominantly as hydromorphone-3-glucuronide (H3G), unchanged hydromorphone (<6%), and other metabolites. Biliary/fecal: minimal.
Primarily renal excretion of unchanged drug (60-70%) and glucuronide conjugates (20-25%); biliary/fecal excretion accounts for 5-10%.
Approximately 20–30%, primarily to albumin.
Highly protein bound (92-95%), primarily to albumin and alpha-1-acid glycoprotein.
1.2–1.8 L/kg. Indicates extensive tissue distribution, consistent with a lipophilic opioid.
0.8-1.2 L/kg; indicates extensive distribution into total body water with some tissue binding.
Oral: 24–51% (first-pass metabolism); Intramuscular: 96% (relative to IV).
Oral: 70-80% due to first-pass metabolism; intramuscular: 90-100%.
GFR 30-60 m L/min: reduce dose by 25-50%; GFR 10-29 m L/min: administer 50-75% of normal dose every 6-8 hours; GFR <10 m L/min: administer 25-50% of normal dose every 8-12 hours.
GFR >50 m L/min: no adjustment; GFR 10-50 m L/min: administer 50% of dose; GFR <10 m L/min: avoid use due to risk of accumulation.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce initial dose by 50%; Child-Pugh Class C: avoid use or reduce dose by 75% with extended dosing interval.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Children >2 years: 0.1-0.2 mg/kg IV/IM/SC every 4-6 hours; maximum single dose 2 mg. Neonates/infants: 0.03-0.05 mg/kg IV/IM/SC every 4-6 hours.
0.01 mg/kg intravenously every 4-6 hours; maximum 0.2 mg/kg/day.
Initial dose: 0.1-0.2 mg IV/IM/SC every 4-6 hours; reduce dose by 50% compared to younger adults; titrate cautiously due to increased sensitivity and risk of respiratory depression.
Initiate with 0.25 mg intravenously every 6 hours; titrate cautiously due to increased sensitivity and renal impairment.
WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CNS DEPRESSANTS; and RISKS OF USE IN PATIENTS WITH HEAD INJURY OR INCREASED INTRACRANIAL PRESSURE.
None
Addiction, abuse, and misuse,Life-threatening respiratory depression,Accidental ingestion,Neonatal opioid withdrawal syndrome,Risks from concomitant use with benzodiazepines or other CNS depressants,Adrenal insufficiency,Severe hypotension,Gastrointestinal effects (constipation, ileus),Seizures,Withdrawal
Increased risk of infections due to immunosuppression,Adrenal suppression with prolonged use,Osteoporosis with long-term use,Exacerbation of diabetes mellitus,Psychiatric disturbances
Significant respiratory depression,Acute or severe bronchial asthma in an unmonitored setting or in absence of resuscitative equipment,Known or suspected gastrointestinal obstruction, including paralytic ileus,Hypersensitivity to hydromorphone or any component of the product
Systemic fungal infections,Hypersensitivity to the drug or any component,Administration of live or live attenuated vaccines
Avoid alcohol while taking DILAUDID-HP, as it can potentiate CNS depression and increase the risk of respiratory depression. Grapefruit juice may inhibit CYP2D6 and CYP3A4 metabolism, potentially increasing hydromorphone levels; avoid concurrent consumption. High-fat meals may delay absorption; maintain consistent timing with or without food.
Avoid grapefruit and grapefruit juice as they may increase drug levels. Take with food to reduce gastrointestinal irritation. Limit sodium intake to reduce fluid retention; consider potassium-rich foods.
FDA Pregnancy Category C. First trimester: No well-controlled human studies; animal studies have shown teratogenicity at high doses. Second and third trimesters: Chronic maternal use may lead to neonatal opioid withdrawal syndrome (NOWS) and respiratory depression at birth. Avoid use during labor due to risk of neonatal respiratory depression.
ALPHADROL is contraindicated in pregnancy. First trimester exposure associated with increased risk of cleft palate, cardiac defects, and neural tube defects. Second and third trimester exposure can cause fetal growth restriction, oligohydramnios, and adrenal suppression. Risk category X.
Hydromorphone is excreted into breast milk. The milk-to-plasma (M/P) ratio is approximately 2.6. Limited data suggest low levels, but use caution due to potential for infant sedation and respiratory depression. The American Academy of Pediatrics considers hydromorphone compatible with breastfeeding if used short-term at low doses.
Excreted into breast milk; M/P ratio not reported. Potential for infant adrenal suppression and growth retardation. Breastfeeding not recommended during therapy and for at least 3 months after last dose.
Pregnancy does not significantly alter hydromorphone pharmacokinetics, but dose adjustments may be needed due to increased pain or opioid tolerance. Use lowest effective dose for shortest duration. Monitor for respiratory depression and adjust accordingly.
Avoid use in pregnancy; no established dose adjustments; use lowest effective dose if unavoidable; increased clearance may require dose increase, but teratogenicity risk precludes use.
DILAUDID-HP (high-potency hydromorphone) is indicated for opioid-tolerant patients only; 1 mg DILAUDID-HP is equivalent to 4 mg standard hydromorphone. Use with extreme caution in patients with respiratory compromise, COPD, or cor pulmonale. Avoid in patients with paralytic ileus or suspected GI obstruction. Monitor for serotonin syndrome when co-administered with serotonergic drugs. For PCA use, ensure proper programming to prevent overdose. Naloxone is the reversal agent; may require higher doses due to high potency.
Monitor blood glucose closely in diabetic patients; may cause hyperglycemia. Administer with food to reduce GI upset. Taper dose over 1-2 weeks after prolonged use to avoid adrenal insufficiency. Avoid live vaccines during therapy.
This is a high-potency opioid; take exactly as prescribed and never increase dose without consulting your doctor.,Do not break, crush, or chew tablets; swallow whole to avoid rapid release of the drug.,Avoid alcohol and other central nervous system depressants (e.g., benzodiazepines, sedatives) as they can increase the risk of severe drowsiness, respiratory depression, and death.,Do not stop taking abruptly; withdrawal symptoms may occur. Consult your doctor for a tapering plan.,Constipation is a common side effect; maintain adequate fluid intake, fiber, and consider stool softeners or laxatives as needed.,Store securely out of reach of children and pets; properly dispose of unused medication at a take-back location.,Seek emergency medical attention if you experience difficulty breathing, extreme drowsiness, confusion, or fainting.,This medication may impair your ability to drive or operate machinery; avoid such activities until you know how it affects you.
Take with food or milk to prevent stomach upset.,Do not stop taking this medication suddenly without consulting your doctor.,Report any signs of infection (fever, sore throat) or unusual bleeding/bruising.,Avoid alcohol while on this medication.,Inform all healthcare providers that you are taking Alphadrol.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DILAUDID-HP vs ALPHADROL, answered by our medical review team.
DILAUDID-HP is a Opioid Analgesic that works by Hydromorphone is a full mu-opioid receptor agonist with high affinity for mu-opioid receptors, producing analgesia, euphoria, and sedation. It also binds to kappa and delta opioid receptors with lower affinity.. ALPHADROL is a Mineralocorticoid that works by Selective glucocorticoid receptor agonist with high potency, binding to the glucocorticoid receptor and modulating gene transcription, leading to anti-inflammatory and immunosuppressive effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DILAUDID-HP and ALPHADROL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DILAUDID-HP is: Initial dose: 0.2-0.6 mg IV/IM/SC every 2-4 hours as needed; usual adult dose: 0.2-0.4 mg IV/IM/SC. Oral: 1-2 mg every 3-6 hours. Dose titration based on pain severity.. The standard adult dose of ALPHADROL is: 0.5 mg intravenously every 4 hours as needed; maximum 2 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DILAUDID-HP and ALPHADROL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DILAUDID-HP is classified as Category C. FDA Pregnancy Category C. First trimester: No well-controlled human studies; animal studies have shown teratogenicity at high doses. Second and third trimesters: Chronic maternal u. ALPHADROL is classified as Category C. ALPHADROL is contraindicated in pregnancy. First trimester exposure associated with increased risk of cleft palate, cardiac defects, and neural tube defects. Second and third trime. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.